Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03919617 · ClinicalTrials.gov registry record · Phase 1
Metabolic Pathways of GRA in Patients With Type 1 Diabetes
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03919617: Completed Phase 1 study, sponsored by University of California, San Diego.
NCT03919617 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03919617, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
A pilot study for individuals with Type 1 Diabetes who are willing to add a GRA (Glucagon Receptor Antagonist) to their current Diabetes treatment regimen. There will be 10 study visits over the course of approximately 8 weeks, with 4 weeks of once weekly, subcutaneous GRA (REMD-477) injection. Testing includes 2 MRI scans, 2 glucose challenges, and 2 insulin withdrawal challenges along with physical assessments and vitals.
Primary Outcome
The change from baseline in peak BHB production as measured by the insulin withdrawal challenge.
Interventions
- DRUG REMD-477
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 1 |
What the finished NCT03919617 record still lists
NCT03919617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which REMD-477 is the first listed.
NCT03919617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03919617 about?
NCT03919617 is a clinical study titled "Metabolic Pathways of GRA in Patients With Type 1 Diabetes". A pilot study for individuals with Type 1 Diabetes who are willing to add a GRA (Glucagon Receptor Antagonist) to their current Diabetes treatment regimen. There will be 10 study visits over the course of approximately 8 weeks, with 4 weeks of once weekly, subcutaneous GRA (REMD-477) injection. Test...
What is the current status of trial NCT03919617?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2019-07-01. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT03919617?
The interventions under investigation include: REMD-477 (DRUG).
Who is sponsoring clinical trial NCT03919617?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03919617's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI